0001493152-20-000994.txt : 20200123
0001493152-20-000994.hdr.sgml : 20200123
20200123171530
ACCESSION NUMBER: 0001493152-20-000994
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200115
FILED AS OF DATE: 20200123
DATE AS OF CHANGE: 20200123
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: 1315 Capital II, L.P.
CENTRAL INDEX KEY: 0001730825
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-24249
FILM NUMBER: 20543009
BUSINESS ADDRESS:
STREET 1: 2929 WALNUT STREET
STREET 2: SUITE 1240
CITY: PHILADELPHIA
STATE: PA
ZIP: 19104
BUSINESS PHONE: 215-662-1315
MAIL ADDRESS:
STREET 1: 2929 WALNUT STREET
STREET 2: SUITE 1240
CITY: PHILADELPHIA
STATE: PA
ZIP: 19104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: INTERPACE BIOSCIENCES, INC.
CENTRAL INDEX KEY: 0001054102
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 222919486
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: MORRIS CORPORATE CENTER 1,
STREET 2: BUILDING C, 300 INTERPACE PARKWAY
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
BUSINESS PHONE: 412-224-6100
MAIL ADDRESS:
STREET 1: MORRIS CORPORATE CENTER 1,
STREET 2: BUILDING C, 300 INTERPACE PARKWAY
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
FORMER COMPANY:
FORMER CONFORMED NAME: Interpace Diagnostics Group, Inc.
DATE OF NAME CHANGE: 20151223
FORMER COMPANY:
FORMER CONFORMED NAME: PDI INC
DATE OF NAME CHANGE: 20021113
FORMER COMPANY:
FORMER CONFORMED NAME: PROFESSIONAL DETAILING INC
DATE OF NAME CHANGE: 19980129
3
1
ownership.xml
X0206
3
2020-01-15
0
0001054102
INTERPACE BIOSCIENCES, INC.
IDXG
0001730825
1315 Capital II, L.P.
C/O INTERPACE BIOSCIENCES, INC.
300 INTERPACE PARKWAY
PARSIPPANY
NJ
07054
0
0
1
0
Series B Convertible Preferred Stock
6.00
Common Stock
3166666
D
The Series B Convertible Preferred Stock, par value $0.01 per share, of the Issuer (the "Series B") is convertible from time to time, at the option of the holder thereof, into a number
of shares of common stock, par value $0.01 per share, of the Issuer (the "Common Stock"), equal to the initial stated value per Series B share of $1,000 (subject to adjustment) divided by
an initial conversion price of $6.00 per share (subject to adjustment) and then multiplied by the number of shares of Series B to be converted. The Series B has no expiration date.
These securities are held of record by the Reporting Person. 1315 Capital Management II, LLC ("1315 Capital Management") is the general partner of the Reporting Person. By virtue
of such relationship, 1315 Capital Management may be deemed to have voting and investment power with respect to the securities held by the Reporting Person noted above and as a
result may be deemed to have beneficial ownership over such securities. Each of the Reporting Person and 1315 Capital Management disclaims beneficial ownership of the securities
reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if
any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purpose of Section 16 of the Securities Exchange Act of
1934, as amended, or for any other purpose.
By 1315 Capital Management II, LLC, its sole general partner, By: Adele C. Oliva, Managing Member /s/ Adele C. Oliva
2020-01-23